DaVita Inc. (NYSE:DVA) Q3 2022 Earnings Conference Call October 28, 2022 8:30 AM ET Company Participants Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - UBS Kevin Fischbeck - Bank of America Pito Chickering - Deutsche Bank Justin Lake - Wolfe Research Operator Good morning. My name is Amanda, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita Third Quarter 2022 Earnings Cal ...

DaVita Inc. (NYSE:DVA) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Corporate Participants Joel Ackerman - Chief Financial Officer and Treasurer Javier Rodriguez - Chief Executive Officer Conference Call Participants Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Pito Chickering - Deutsche Bank Sarah James - Barclays Gary Taylor - Cowen Operator Good evening. My name is Michelle, and I’ll be your conference facilitator today. At this time, I’d like to welcome everyone to the D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th Street ...

DaVita Inc. (NYSE:DVA) Q1 2022 Results Conference Call May 5, 2022 5:00 PM ET Company Participants Joel Ackerman - CFO and Treasurer Javier Rodriguez - CEO Conference Call Participants Kevin Fischbeck - Bank of America Justin Lake - Wolfe Research Pito Chickering - Deutsche Bank Operator Good evening. My name is Missy, and I’ll be your conference facilitator today. At this time, I’d like to welcome everyone to the DaVita First Quarter 2022 Earnings Call. [Operator Instructions] Thank you. Mr. Ackerman, you ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |--------------------------------------|------------------------------------------|--------------------| | | | | | For the | transition period from ___________ | to ___________ | | ...

DaVita Inc.’s (NYSE:DVA) Q4 2021 Earnings Conference Call February 10, 2022 5:00 PM ET Company Participants Jim Gustafson - Vice President of Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Sarah James - Barclays Justin Lake - Wolfe Research Pito Chickering - Deutsche Bank Kevin Fischbeck - Bank of America Gary Taylor - Cowen Lisa Clive - Bernstein Operator Good evening. My name is Michelle and I will be your conference facil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. (Exact name of registrant as specified in charter) Delaware 51-0354549 (State of incorporation) (I.R.S. ...

DaVita Inc.'s (NYSE:DVA) Q3 2021 Earnings Conference Call October 28, 2021 5:00 PM ET Company Participants Jim Gustafson - Vice President of Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Justin Lake - Wolfe Research Kevin Fischbeck - Bank of America Pito Chickering - Deutsche Bank Sarah James - Barclays Lisa Clive - Bernstein Gary Taylor - Cowen Operator Good evening. My name is Michelle and I will be your conference facili ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th St ...

Financial Performance - The company reported a 6% year-over-year growth in adjusted operating income and a 35% year-over-year growth in adjusted earnings per share [10] - Operating income for the quarter was $490 million, and earnings per share were $2.64 [20] - Free cash flow was strong, and the company continued to return cash to shareholders through stock buybacks [10] Business Lines and Key Metrics - Treatments per day increased by 0.4% compared to Q1, with excess mortality declining significantly from approximately 3,000 in Q1 to fewer than 500 in Q2 [21] - U.S. dialysis revenue per treatment grew sequentially by almost $6, primarily due to seasonal improvements and favorable changes in government rate and mix [22] - Patient care costs decreased sequentially, primarily due to reductions in labor costs, while G&A expenses increased slightly [22] Market Data and Key Metrics - Approximately 10% of U.S. dialysis patients are in value-based care arrangements, representing almost $2 billion of annual medical costs under management [14] - The company expects its integrated kidney care business to double in size in 2022, both in the number of patients and risk arrangements [14] Company Strategy and Industry Competition - The company is focusing on integrated kidney care (IKC) to improve patient outcomes and reduce total healthcare costs [11] - The trend towards value-based care is gaining momentum, with the company preparing to partner with nephrologists in multiple markets starting in January [12] - The company believes it is well-positioned to win in integrated care due to strong partnerships and a broad kidney care platform [13] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about returning to pre-pandemic treatment growth levels, with an additional tailwind from lower-than-normal mortality rates [21] - The company raised its guidance for 2021, expecting adjusted earnings per share of $8.80 to $9.40 and adjusted operating income of $1.8 billion to $1.875 billion [24] - Potential headwinds include COVID-related costs and losses in the U.S. ancillary segment due to new value-based care arrangements [25][27] Other Important Information - The company is collaborating with the National Kidney Foundation on a pilot aimed at improving health equity in kidney transplantation [7] - The vaccination rates for patients and teammates are approximately 72% and 68%, respectively [55] Q&A Session Question: Can you remind us how the IKC flows through the P&L? - The U.S. component of strategic initiatives serves as a proxy for the IKC P&L, and the company will disclose medical costs under management [30] Question: What is the expected treatment growth rate once normalized? - Management believes treatment growth will revert to pre-COVID levels, with strong new dialysis admissions continuing [48] Question: What is the impact of COVID on the second half of the year? - The company expects a $30 million headwind from COVID in the second half of the year compared to the first half [26] Question: How will the company manage labor costs? - The company is actively investing in a differentiated workplace to attract and retain talent amid a competitive labor market [49] Question: What is the vaccination strategy for patients and teammates? - The company tests patients with symptoms and tracks vaccination rates, with no significant numbers reported for third doses yet [55][56]